SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced the appointment of Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Based in the United States, Romano brings more than two decades of finance leadership experience in the medical technology and life sciences sectors. She will help lead the company’s financial operations as it advances its global expansion strategy, including pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Most recently, Romano served as chief financial officer of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting and investor relations.
The appointment comes at a critical time for SS Innovations as the company seeks to expand the global presence of its SSi Mantra surgical robotic system. The system, along with its comprehensive suite of SSi Mudra surgical instruments, supports a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations aims to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population.
Romano’s extensive experience in raising capital and managing financial operations in the life sciences sector will be instrumental as SS Innovations pursues FDA approval and expands its footprint. Her track record of reducing cash burn and strengthening balance sheets aligns with the company’s strategic objectives to advance its technology and bring cost-effective surgical robotic solutions to market.
For more details, the full press release is available at https://ibn.fm/pAqlP.
This announcement underscores SS Innovations’ commitment to growth and innovation in surgical robotics, positioning the company to potentially transform the landscape of minimally invasive surgery. The addition of Romano to the executive team signals a focus on financial discipline and strategic capital management as the company navigates regulatory pathways and global expansion.
Forward-looking statements in this article involve risks and uncertainties. For a discussion of these factors, refer to the company's filings with the SEC, including the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
